• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Yale, Mayo Clinic, Biofourmis Launches Research to Detect Heart Failure Using Wearable Biosensor Data

by Jasmine Pennic 07/17/2019 Leave a Comment

Yale, Mayo Clinic, Biofourmis Launches Research to Detect Heart Failure Using Wearable Biosensor Data

Biofourmis has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.

Impact of Heart Failure

Heart failure afflicts approximately 6.5 million patients in the United States and 26 million worldwide, causing substantial mortality and morbidity, and has major effects on physical function and quality of life. FDA recognizes in its recent draft guidance, Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry, that an effect on symptoms or physical function, without a favorable effect on survival or risk of hospitalization can be a basis for approving drugs to treat heart failure.

“This joint project has the potential to advance the science of clinical trial design,” said Kuldeep Singh Rajput, CEO of Biofourmis. “Ultimately, this study could open the door for regulatory agencies to consider including patient-centric endpoints in the drug approval process—which could potentially speed the regulatory approval process.”

Yale-Mayo CERSI Overview

The Yale-Mayo CERSI is a joint effort between Yale University, Mayo Clinic and the U.S. Food & Drug Administration (FDA). CERSIs are collaborations between FDA and academic institutions to advance regulatory science through innovative research, training and scientific exchanges. To demonstrate the feasibility and reliability of capturing these new patient-centric endpoints, Biofourmis and Yale-Mayo CERSI will conduct a multicenter study beginning in August 2019 of recently discharged patients with heart failure, who will be screened and then monitored at home for 60 days.

Using Wearable Biosensors to Detect Heart Failure

Patients will be monitored using Biofourmis’ BiovitalsHFTM, which is a sensor-agnostic mobile health platform compatible with leading clinically validated, FDA cleared, and medical CE-marked wearable biosensors. BiovitalsHFTM captures raw biosensor data and uses advanced machine learning to derive dozens of physiology biomarkers and is able to detect heart failure decompensation using multi-variate physiology analytics, weeks in advance.

Study Details

In this study, BiovitalsHFTM will be used to capture multiple physiology biomarkers and physical activity continuously in real-world settings, using two wearable biosensors: a medical-grade device called Everion® and the consumer wearable smartwatch Apple Watch Series. Apart from using the BiovitalsHFTM patient-facing companion app for syncing physiology data from sensors, it will be used to capture electronic patient-reported outcomes (ePROs) such as medication adherence, symptoms, the Kansas City Cardiomyopathy Questionnaire (KCCQ) responses, and the guided mobile-based 2-minute-step-test.

The primary goal of the study is to measure the correlation between physiology and actigraphy biomarkers with clinical endpoints such as lab results, the KCCQ, and the six-minute walk test (6MWT). The data also will be used to assess medication adherence, dose changes and percentage of patients on target dosages of Guideline Directed Heart Failure Therapies.

Why It Matters

“Biofourmis is a leader in the emerging field of digital therapeutics, and we are thrilled to be partnering with them on this important study,” said Nilay Shah, PhD, Principal Investigator at the Yale University-Mayo Clinic CERSI. “This study will not only advance science, but will also provide insights to the FDA on how these measures can be used as alternative trial endpoints.”

Rajput explained: “We have entered into a new era in clinical trial design that encourages patient engagement and values quality of life. By leveraging our user experience, powerful data-analytic capabilities and vendor-agnostic sensor compatibility, we are excited about the prospect that Biofourmis will play a part in establishing new patient-centric endpoints for clinical trials, starting with heart failure.”

Tagged With: apple, Apple Watch, Biofourmis, Biomarkers, Biosensors, Clinical Trial, Clinical Trials, Digital Therapeutics, FDA, Heart, Machine Learning, Mayo Clinic, medication, Medication Adherence, mobile health, patient engagement, PhD, risk, sensors, Smartwatch

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |